Teva Announces the Launch of Generic Vagifem® in the United States

Business Wire: July 24, 2017 – JERUSALEM, Israel – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of Vagifem® 1 (estradiol vaginal inserts), 10 mcg in the United States. Estradiol vaginal inserts are an estrogen indicated for the treatment of atrophic vaginitis due to menopause.

Estradiol vaginal inserts add to Teva’s existing portfolio of more than 70 women’s health products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the United States. Currently, one in six generic prescriptions dispensed in the United States is filled with a Teva generic product.

“Our expanding portfolio of oral contraceptives and hormone replacement therapies gives women a broader choice of products to manage their health needs cost-effectively,” said Andy Boyer, CEO and president, global generic medicines, North America, at Teva. “With this addition, patients and healthcare providers who prefer this unique dosage-form now have another, more affordable option for treatment.”

Estradiol vaginal inserts had annual sales of approximately $379 million in the United States according to IMS data as of May 2017.